ORIGINAL ARTICLE
Does loss of ARID1A expression affect neoadjuvant chemoradiotherapy response in rectal carcinomas?
1
Department of Pathology, Kartal Dr. Lutfi Kirdar City Hospital, University of Health Sciences, Istanbul, Turkey
2
Department of Pathology, Medical Faculty, Istinye University, Istanbul, Turkey
3
Pathology Clinic, Midyat State Hospital, Mardin, Turkey
4
Pathology Clinic, Batman Training and Research Hospital, Batman, Turkey
Submission date: 2025-05-26
Acceptance date: 2025-07-08
Publication date: 2025-09-22
Corresponding author
Sibel Sensu
Sibel Sensu Department of Pathology, Medical Faculty, Istinye University, Istanbul, Turkey
Sibel Sensu Department of Pathology, Medical Faculty, Istinye University, Istanbul, Turkey
Pol J Pathol 2025;76(2):87-93
KEYWORDS
TOPICS
ABSTRACT
This study evaluated the difference of ARID1A protein immunoexpression between responders and non-responders to neoadjuvant chemoradiotherapy in locally advanced rectal cancers.
The biopsies before neoadjuvant chemoradiotherapy and resection materials after mesorectal excision were re-examined for conventional prognostic parameters, tumour regression score was determined, and survival data were evaluated. All parameters were statistically compared.
Of the 117 cases, most (93%) were adenocarcinoma, 88% were moderately differentiated and no response was seen in 28%. Before neoadjuvant therapy, low nuclear expression of ARID1A was noted in 49 (41.9%), while high expression was observed in 68 cases (58.1%). After neoadjuvant therapy, low expression was observed in 12 (10.7%) cases, while high expression was seen in 90 cases (80.3%). After neoadjuvant therapy a statistically lower ARID1A expression was noted in the absence of distant organ metastasis (p = 0.033). No statistically significant relationship was observed between ARID1A expression and overall survival or progression-free survival. ARID1A expression before neoadjuvant treatment had no statistically significant effect on response to neoadjuvant treatment and was not significantly associated with survival.
More patients had significantly higher ARID1A expression in the post-treatment period than the pretreatment period. This may suggest that tumour cells with low ARID1A expression are more sensitive to neoadjuvant therapy.
The biopsies before neoadjuvant chemoradiotherapy and resection materials after mesorectal excision were re-examined for conventional prognostic parameters, tumour regression score was determined, and survival data were evaluated. All parameters were statistically compared.
Of the 117 cases, most (93%) were adenocarcinoma, 88% were moderately differentiated and no response was seen in 28%. Before neoadjuvant therapy, low nuclear expression of ARID1A was noted in 49 (41.9%), while high expression was observed in 68 cases (58.1%). After neoadjuvant therapy, low expression was observed in 12 (10.7%) cases, while high expression was seen in 90 cases (80.3%). After neoadjuvant therapy a statistically lower ARID1A expression was noted in the absence of distant organ metastasis (p = 0.033). No statistically significant relationship was observed between ARID1A expression and overall survival or progression-free survival. ARID1A expression before neoadjuvant treatment had no statistically significant effect on response to neoadjuvant treatment and was not significantly associated with survival.
More patients had significantly higher ARID1A expression in the post-treatment period than the pretreatment period. This may suggest that tumour cells with low ARID1A expression are more sensitive to neoadjuvant therapy.
REFERENCES (26)
1.
Conces ML, Mahipal A. Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer. Curr Oncol 2024; 31: 366-382.
2.
Feeney G, Sehgal R, Sheehan M, et al. Neoadjuvant radiotherapy for rectal cancer management. World J Gastroenterol 2019; 25: 4850-4869.
3.
Mullen J, Kato S, Sicklick JK, Kurzrock R. Targeting ARID1A mutations in cancer. Cancer Treat Rev 2021; 100: 102287.
4.
Xu S, Tang C. The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression? Front Oncol 2021; 11: 745187.
5.
Peerapen P, Sueksakit K, Boonmark W, Yoodee S, Thongboonkerd V. ARID1A knockdown enhances carcinogenesis features and aggressiveness of Caco-2 colon cancer cells: An in vitro cellular mechanism study. J Cancer 2022; 13: 373-384.
6.
Pavlidou EN, Balis V. Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes. World Acad Sci J 2020; 2: 49-64.
7.
Ruijtenberg S, van den Heuvel S. Coordinating cell proliferation and differentiation: Antagonism between cell cycle regulators and cell type-specific gene expression. Cell Cycle 2016; 15: 196-212.
8.
Kim SM, Yoon G, Seo AN. What are the most important prognostic factors in patients with residual rectal cancer after preoperative chemoradiotherapy? Yeungnam Univ J Med 2019; 36: 124-135.
9.
Kolorektal Kanser Klinik Protokolü. Versiyon 1.0. T.C. Saglik Bakanligi Saglik Hizmetleri Genel Müdürlügü Saglik Teknolojisi Degerlendirme Daire Baskanligi. Available at: https://dosyamerkez.saglik.gov... E718E04C56EECD2BD5363253461F6B7E3.
10.
Ryan R, Gibbons D, Hyland JM, et al. The pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005; 47: 141-146.
11.
Sun D, Zhu, Y, Zhao H, et al. Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis. Cell Oncol 2021; 44: 1019-1034.
12.
Wang T, Guo J, Liu W, et al. Downregulation of ARID1A is correlated with poor prognosis in non-small cell lung cancer. Transl Cancer Res 2020; 9: 4896-4905.
13.
Katz M, Amit I, Citri A, et al. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol 2007; 9: 961-969.
14.
Chen K, Collins G, Wang H, Toh JWT. Pathological Features and Prognostication in Colorectal Cancer. Curr Oncol 2021; 28: 5356-5383.
15.
Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw 2020; 18: 806-815.
16.
Deschner BW, VanderWalde NA, Grothey A, Shibata D. Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer. JCO Oncol Pract 2021; 17: 383-402.
17.
Leeds IL, Fang SH. Neoadjuvant Therapy for Rectal Cancer. Dis Colon Rectum 2018; 61: 883-886.
18.
Wei XL, Wang DS, Xi SY, et al. Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World J Gastroenterol 2014; 20: 18404-18412.
20.
Chen HY, Feng LL, Li M, et al. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer. Oncologist 2021; 26: e780-e793.
21.
Tong Y, Liu D, Zhang J. Connection and distinction of tumor regression grading systems of gastrointestinal cancer. Pathol Res Pract 2020; 216: 153073.
22.
Douglas JK, Callahan RE, Hothem ZA, et al. Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer. Mol Cell Oncol 2020; 7: 1716618.
23.
Unçel M, Diniz G, Akoz G, et al. Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. Eur J Breast Health. 2019; 15: 125-129.
24.
Khosrowjerdi SJ, Horick NK, Clark JW, et al. Clinical and mutational profile of ARID1A-mutated gastrointestinal cancers: Duration of response to platinum-based chemotherapy. J Clin Oncol 2021; 39: e15611-e15611.
25.
Erfani M, Hosseini SV, Mokhtari M, et al. Altered ARID1A expression in colorectal cancer. BMC Cancer 2020; 20: 350.
26.
Fontana B, Gallerani G, Salamon I, Pace I, Roncarati R, Ferracin M. ARID1A in cancer: Friend or foe? Front Oncol 2023; 13: 1136248.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
